Randomized Double-Blind, Placebo- Controlled Phase 2 Trial of NuGel, an Inflammasome Inhibitor, for Atopic Dermatitis
Time: 12:00 pm
day: Day 2 - Track B - Morning
Details:
- A novel inflammasome inhibitor targeting GPCR19
- GPCR19-P2X7R complex regulating NLRP3 inflammasome
- Efficient regulation of clinical symptoms assessed by EASI score
